STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
In its organising meeting, the Board of Directors of
The compositions of the Board committees were decided to be as follows:
Hilpi Rautelin
Audit Committee:
Henrik Stenqvist
R&D Committee:
Hilpi Rautelin, Chairman
The Company also has a Nomination Committee, the election of which was announced in a Stock Exchange Release on
All members of the Board of Directors have been assessed to be independent of the company and its significant shareholders.
President and CEO | SVP, Corporate Functions |
Contact person:
SVP, Corporate Functions
tel. +358 50 966 3054
Publisher:
Communications
Orionintie 1A, FI-02200
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to
© OMX, source